Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of anaplerotic treatment on brain energy profile evolution in early stage of the Huntington disease

Next Previous
X
Search
Trial Profile

Effect of anaplerotic treatment on brain energy profile evolution in early stage of the Huntington disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications Huntington's disease
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms TRIHEP2

    • Most Recent Events

    • 07 Jan 2015 According to an Ultragenyx Pharmaceutical media release, results were published in the online issue of Neurology in 2015.
    • 12 Aug 2013 New trial record
    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top